nanotech-investing Nuvation Bio Announces Pivotal Global Phase 3 SIGMA Trial for Safusidenib in IDH1-Mutant Glioma 09 February
nanotech-investing Nuvation Bio Reports Preliminary Fourth Quarter and Full Year 2025 Financial Results and Provides 2026 Outlook Ahead of 44th Annual J.P. Morgan Healthcare Conference 12 January
nanotech-investing Nuvation Bio and Eisai Enter into Exclusive Licensing Agreement for Taletrectinib in Europe and Additional Countries Outside U.S., China and Japan 12 January
